ASP1650

· Astellas Pharma Global Development, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ASP1650, covering 2021-11-10 to 2021-11-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors [Phase 2]

See pricing